Welcome to LookChem.com Sign In|Join Free

CAS

  • or

158001-20-8

Hydrazinecarboxylic acid, cyclobutylidene-, 1,1-dimethylethyl ester (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

158001-20-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

  • Hydrazinecarboxylic acid, cyclobutylidene-, 1,1-dimethylethyl ester (9CI)

    Cas No: 158001-20-8

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 158001-20-8 Structure

  • Basic information

    1. Product Name: Hydrazinecarboxylic acid, cyclobutylidene-, 1,1-dimethylethyl ester (9CI)
    2. Synonyms: Hydrazinecarboxylic acid, cyclobutylidene-, 1,1-dimethylethyl ester (9CI);tert-butyl2-cyclobutylidenehydrazine-1-carboxylate;tert-butyl 2-cyclobutylidenehydrazinecarboxylate(WX191453);TERT-BUTYL CYCLOBUTYLIDENECARBAZATE;N-Cyclobutylidene-hydrazinecarboxylic acid tert-butyl ester
    3. CAS NO:158001-20-8
    4. Molecular Formula: C9H16N2O2
    5. Molecular Weight: 184.23554
    6. EINECS: N/A
    7. Product Categories: N-BOC
    8. Mol File: 158001-20-8.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.11±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 10.97±0.20(Predicted)
    10. CAS DataBase Reference: Hydrazinecarboxylic acid, cyclobutylidene-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
    11. NIST Chemistry Reference: Hydrazinecarboxylic acid, cyclobutylidene-, 1,1-dimethylethyl ester (9CI)(158001-20-8)
    12. EPA Substance Registry System: Hydrazinecarboxylic acid, cyclobutylidene-, 1,1-dimethylethyl ester (9CI)(158001-20-8)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 158001-20-8(Hazardous Substances Data)

158001-20-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 158001-20-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,8,0,0 and 1 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 158001-20:
(8*1)+(7*5)+(6*8)+(5*0)+(4*0)+(3*1)+(2*2)+(1*0)=98
98 % 10 = 8
So 158001-20-8 is a valid CAS Registry Number.

158001-20-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name N'-cyclobutylidene-hydrazinecarboxylic acid tert-butyl ester

1.2 Other means of identification

Product number -
Other names N'-cyclobutylidenehydrazinecarboxylic acid tert-butyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:158001-20-8 SDS

158001-20-8Relevant articles and documents

COMPOUNDS USEFUL AS KINASE INHIBITORS

-

Paragraph 00295, (2017/07/14)

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

CARBOXAMIDE DERIVATIVES

-

Paragraph 0806-0807, (2015/12/17)

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Compounds for the Treatment of Hepatitis C

-

Page/Page column 30, (2009/12/04)

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase

-

Page/Page column 66, (2008/06/13)

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 158001-20-8